keyword
MENU ▼
Read by QxMD icon Read
search

Total PSA Free PSA

keyword
https://www.readbyqxmd.com/read/28636187/dual-labeled-chemiluminescence-enzyme-immunoassay-for-simultaneous-measurement-of-total-prostate-specific-antigen-tpsa-and-free-prostate-specific-antigen-fpsa
#1
Lixia Zhao, Dan Wang, Gen Shi, Ling Lin
The specificity for early diagnostic of prostate-specific antigen (PSA) is low because the current technology mostly allows the detection of only one biomarker at one time. In this work, a dual-labeled chemiluminescence enzyme immunoassay (CLEIA) for simultaneous measurement of total PSA (TPSA) and free PSA (FPSA) was proposed. Anti-PSA McAb (Mab1) was immobilized on a microplate as the solid phase, horseradish peroxidase (HRP)-labeled anti-TPSA monoclonal antibody (McAb2) and alkaline phosphatase (ALP)-labeled anti-FPSA McAb3 were used as detection antibodies...
June 21, 2017: Luminescence: the Journal of Biological and Chemical Luminescence
https://www.readbyqxmd.com/read/28624848/-177-lu-psma-617-radioligand-therapy-and-outcome-in-patients-with-metastasized-castration-resistant-prostate-cancer
#2
Axel Bräuer, Lena Sophie Grubert, Wolfgang Roll, Andres Jan Schrader, Michael Schäfers, Martin Bögemann, Kambiz Rahbar
PURPOSE: Radioligand therapies targeting prostate-specific membrane antigen (PSMA) have been established for the treatment of metastasized castration-resistant prostate cancer (mCRPC) in the last decade and show promising response rates and a favourable toxicity profile. The aim of this study was to evaluate the overall survival (OS) and to identify parameters predicting outcome in mCRPC patients treated with (177)Lu-PSMA-617. METHODS: Between December 2014 and January 2017, 59 consecutive patients (median age 72 years; interquartile range, (IQR, 66-76 years) with mCRPC, who had been treated with at least one next-generation antihormonal drug as well as chemotherapy, were included in this study...
June 17, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28623636/eleven-year-management-of-prostate-cancer-patients-on-active-surveillance-what-have-we-learned
#3
Cristina Marenghi, Maria Francesca Alvisi, Federica Palorini, Barbara Avuzzi, Fabio Badenchini, Nice Bedini, Lara Bellardita, Davide Biasoni, Davide Bosetti, Alessandra Casale, Mario Catanzaro, Maurizio Colecchia, Letizia De Luca, Simona Donegani, Paola Dordoni, Rodolfo Lanocita, Massimo Maffezzini, Tiziana Magnani, Julia Menichetti, Antonella Messina, Sara Morlino, Biagio Paolini, Tiziana Rancati, Silvia Stagni, Antonio Tesone, Tullio Torelli, Edoardo Tulli Baldoin, Marta Vaiani, Sergio Villa, Silvia Villa, Nadia Zaffaroni, Nicola Nicolai, Roberto Salvioni, Riccardo Valdagni
PURPOSE: To evaluate the outcomes of active surveillance (AS) on patients with low-risk prostate cancer (PCa) and to identify predictors of disease reclassification. METHODS: In 2005, we defined an institutional AS protocol (Sorveglianza Attiva Istituto Nazionale Tumori [SAINT]), and we joined the Prostate Cancer Research International: Active Surveillance (PRIAS) study in 2007. Eligibility criteria included clinical stage ≤T2a, initial prostate-specific antigen (PSA) <10 ng/mL, and Gleason Pattern Score (GPS) ≤3 + 3 (both protocols); ≤25% positive cores with a maximum core length containing cancer ≤50% (SAINT); and ≤2 positive cores and PSA density <0...
June 14, 2017: Tumori
https://www.readbyqxmd.com/read/28622770/intensity-modulated-radiation-therapy-from-70gy-to-80gy-in-prostate-cancer-six-year-outcomes-and-predictors-of-late-toxicity
#4
Maria Jolnerovski, Julia Salleron, Véronique Beckendorf, Didier Peiffert, Anne-Sophie Baumann, Valérie Bernier, Sandrine Huger, Vincent Marchesi, Ciprian Chira
OBJECTIVE: To report grade ≥2 overall late rectal and urinary toxicities in patients (pts) with prostate cancer treated by intensity-modulated radiotherapy (IMRT) at 3 dose-levels. Identify predictors of radiation toxicity and report biochemical progression free survival (bPFS). METHODS: A total of 277 pts were treated with 70Gy (10.8%), 74Gy (63.9%) and 80 Gy (25.3%) using IMRT without pelvic irradiation were analyzed. Short or long-course androgen deprivation therapy (ADT) was allowed in 46...
June 16, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/28613202/-comparison-of-two-on-line-risk-calculators-versus-the-detection-of-circulating-prostate-cells-for-the-detection-of-high-risk-prostate-cancer-at-first-biopsy
#5
Nigel P Murray, Cynthia Fuentealba, Eduardo Reyes, Omar Jacob
OBJECTIVE: The limitations of total serum PSA values remains problematic; nomograms may improve the prediction of a positive prostate biopsy (PB). We compare in a prospective study of Chilean men with suspicion of prostate cancer due to an elevated total serum PSA and/or abnormal digital rectal examination, the use of two on-line nomograms with the detection of primary malignant circulating prostate cells (CPCs) to predict a positive PB for high risk prostate cancer. METHODS: Consecutive men with suspicion of prostate cancer underwent 12 core TRUS prostate biopsy...
June 2017: Archivos Españoles de Urología
https://www.readbyqxmd.com/read/28605139/clinical-implications-of-pretreatment-inflammatory-biomarkers-as-independent-prognostic-indicators-in-prostate-cancer
#6
Zhaohui Sun, Ying Ju, Fuyan Han, Xiya Sun, Fang Wang
OBJECTIVES: Research on the relationship between inflammatory biomarkers and malignant tumors has become a hotspot. Many studies have demonstrated that neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and red blood cell distribution width (RDW) could act as independent prognostic indicators for several solid tumors. This study aimed to evaluate the clinical implications of pretreatment inflammatory biomarkers, including NLR, PLR, and RDW as independent prognostic indicators in prostate cancer (PCa)...
June 12, 2017: Journal of Clinical Laboratory Analysis
https://www.readbyqxmd.com/read/28593167/correlation-between-postoperative-prostate-specific-antigen-and-biochemical-recurrence-in-positive-surgical-margin-patients-single-surgeon-series
#7
Won Ik Seo, Pil Moon Kang, Jang Ho Yoon, Wansuk Kim, Jae Il Chung
BACKGROUND: To evaluate the relationship between postoperative prostate-specific antigen (PSA) levels and biochemical recurrence (BCR) after radical prostatectomy, especially in patients with positive surgical margins (PSMs). MATERIALS AND METHODS: A total of 144 patients who underwent radical prostatectomies performed by a single surgeon without any neoadjuvant or adjuvant treatment were analyzed. Differences in clinicopathological factors were compared by surgical margin status, and the relationship between postoperative PSA level and BCR in patients with PSMs was evaluated...
June 2017: Prostate International
https://www.readbyqxmd.com/read/28578639/abiraterone-for-prostate-cancer-not-previously-treated-with-hormone-therapy
#8
Nicholas D James, Johann S de Bono, Melissa R Spears, Noel W Clarke, Malcolm D Mason, David P Dearnaley, Alastair W S Ritchie, Claire L Amos, Clare Gilson, Rob J Jones, David Matheson, Robin Millman, Gerhardt Attard, Simon Chowdhury, William R Cross, Silke Gillessen, Christopher C Parker, J Martin Russell, Dominik R Berthold, Chris Brawley, Fawzi Adab, San Aung, Alison J Birtle, Jo Bowen, Susannah Brock, Prabir Chakraborti, Catherine Ferguson, Joanna Gale, Emma Gray, Mohan Hingorani, Peter J Hoskin, Jason F Lester, Zafar I Malik, Fiona McKinna, Neil McPhail, Julian Money-Kyrle, Joe O'Sullivan, Omi Parikh, Andrew Protheroe, Angus Robinson, Narayanan N Srihari, Carys Thomas, John Wagstaff, James Wylie, Anjali Zarkar, Mahesh K B Parmar, Matthew R Sydes
Background Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate cancer. We assessed the effect of this combination in men starting long-term androgen-deprivation therapy (ADT), using a multigroup, multistage trial design. Methods We randomly assigned patients in a 1:1 ratio to receive ADT alone or ADT plus abiraterone acetate (1000 mg daily) and prednisolone (5 mg daily) (combination therapy). Local radiotherapy was mandated for patients with node-negative, nonmetastatic disease and encouraged for those with positive nodes...
June 3, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28557065/lactate-dehydrogenase-predicts-combined-progression-free-survival-after-sequential-therapy-with-abiraterone-and-enzalutamide-for-patients-with-castration-resistant-prostate-cancer
#9
Keiichiro Mori, Takahiro Kimura, Hajime Onuma, Shoji Kimura, Toshihiro Yamamoto, Hiroshi Sasaki, Jun Miki, Kenta Miki, Shin Egawa
BACKGROUND: An array of clinical issues remains to be resolved for castration-resistant prostate cancer (CRPC), including the sequence of drug use and drug cross-resistance. At present, no clear guidelines are available for the optimal sequence of use of novel agents like androgen-receptor axis-targeted (ARAT) agents, particularly enzalutamide, and abiraterone. METHODS: This study retrospectively analyzed a total of 69 patients with CRPC treated with sequential therapy using enzalutamide followed by abiraterone or vice versa...
May 30, 2017: Prostate
https://www.readbyqxmd.com/read/28551659/chronic-periodontitis-does-not-impact-serum-levels-of-prostate-specific-antigen
#10
Stephan Kruck, Jörg Hennenlotter, Bastian Amend, Maya Geiger, Elitsa Filipova, Tim Neumann, Viktoria Stühler, Tina Schubert, Tilman Todenhöfer, Steffen Rausch, Fabian Huettig, Arnulf Stenzl, Jens Bedke
BACKGROUND/AIM: Chronic periodontitis (CP) has already been associated with altered PSA values in men undergoing biopsy. This study addressed the impact of CP treatment on PSA screening. PATIENTS AND METHODS: Fifty-two asymptomatic men presenting for CP treatment were prospectively enrolled. Total (t)PSA, free (f)PSA and %PSA were determined (n=47) before and after therapy. Pre- and post-therapy values were correlated pairwise regarding patients and dental characteristics...
June 2017: Anticancer Research
https://www.readbyqxmd.com/read/28548372/initial-multicentre-experience-of-68-gallium-psma-pet-ct-guided-robot-assisted-salvage-lymphadenectomy-acceptable-safety-profile-but-oncological-benefit-appears-limited
#11
Amila Siriwardana, James Thompson, Pim J van Leeuwen, Shaela Doig, Anton Kalsbeek, Louise Emmett, Warick Delprado, David Wong, Hemamali Samaratunga, Anne-Maree Haynes, Geoff Coughlin, Phillip Stricker
OBJECTIVES: To evaluate the safety and short-term oncological outcomes for (68) Ga-PSMA PET/CT directed robot-assisted salvage node dissection (RASND) for prostate cancer oligometastatic nodal recurrence. MATERIALS AND METHODS: Between February 2014 and April 2016, 35 patients across two centres underwent RASND for (68) Ga-PSMA PET/CT detected oligometastatic nodal recurrence. RASND was performed by targeted pelvic dissection, unilateral extended pelvic template or bilateral extended pelvic template dissection, depending on previous pelvic treatment and extent/location of nodal disease...
May 26, 2017: BJU International
https://www.readbyqxmd.com/read/28540788/salvage-focal-cryosurgery-may-delay-use-of-androgen-deprivation-therapy-in-cryotherapy-and-radiation-recurrent-prostate-cancer-patients
#12
Michael Kongnyuy, Courtney J Berg, Kaitlin E Kosinski, David J Habibian, Jeffrey T Schiff, Anthony T Corcoran, Aaron E Katz
INTRODUCTION: Salvage treatment options for recurrent unilateral prostate cancer (PCa) after primary radiation are limited and associated with severe complications and poor quality of life measures. Salvage focal cryotherapy (SFC) has shown success in biochemical recurrence (BCR) free survival. We aim to determine if SFC can delay use of androgen deprivation therapy (ADT) in recurrent PCa with low morbidity. METHODS: A retrospective review of patients who underwent SFC at our institution from 2007 to 2015 was performed...
March 29, 2017: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/28532400/oligometastases-from-prostate-cancer-local-treatment-with-stereotactic-body-radiotherapy-sbrt
#13
Gregor Habl, Christoph Straube, Kilian Schiller, Marciana Nona Duma, Markus Oechsner, Kerstin A Kessel, Matthias Eiber, Markus Schwaiger, Hubert Kübler, Jürgen E Gschwend, Stephanie E Combs
BACKGROUND: The impact of local tumor ablative therapy in oligometastasized prostate cancer (PC) is still under debate. To gain data for this approach, we evaluated oligometastasized PC patients receiving stereotactic body radiotherapy (SBRT) to bone metastases. METHODS: In this retrospective study, 15 oligometastasized PC patients with a total of 20 bone metastases were evaluated regarding biochemical progression-free survival (PSA-PFS), time to initiation of ADT, and local control rate (LCR)...
May 22, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28529023/clinical-efficacy-of-transrectal-ultrasound-guided-prostate-biopsy-in-men-younger-than-50-years-old-with-an-elevated-prostate-specific-antigen-concentration-4-0%C3%A2-ng-ml
#14
Chin-Heng Lu, Tzu-Ping Lin, She Huei Shen, Yi-Hsiu Huang, Hsiao-Jen Chung, Junne-Yih Kuo, William J S Huang, Howard H H Wu, Yen-Hwa Chang, Alex T L Lin, Kuang-Kuo Chen
BACKGROUND: Prostate cancer (PCa) is not commonly found in men younger than 50 years of age. However, serum prostate-specific antigen (PSA) concentration has been examined more frequently at a younger age in Asia partially due to an increased awareness of prostate cancer. The purpose of our study was to investigate the efficacy and complication of PSA-triggered transrectal ultrasonography-guided prostate (TRUSP) biopsies. We retrospectively reviewed TRUSP biopsies in young men with elevated PSA concentration in Taipei Veterans General Hospital...
May 18, 2017: Journal of the Chinese Medical Association: JCMA
https://www.readbyqxmd.com/read/28523407/heterogeneous-oncologic-outcomes-according-to-surgical-pathology-in-high-risk-prostate-cancer-implications-for-better-risk-stratification-and-preoperative-prediction-of-oncologic-outcomes
#15
Seung-Kwon Choi, Myungsun Shim, Myong Kim, Myungchan Park, Sangmi Lee, Cheryn Song, Hyung-Lae Lee, Hanjong Ahn
PURPOSE: To evaluate the better risk stratification based on surgical pathology, and to predict oncologic outcomes after radical prostatectomy (RP) with a better scoring system in high-risk prostate cancer (PCa) patients. METHODS: We evaluated high-risk PCa patients (PSA >20 ng/ml, ≥cT3a, or Gleason score 8-10) who underwent RP between 2007 and 2013 at our institute. We classified patients into three groups according to their pathologic outcomes: favorable (pT2, Gleason score ≤7, and node negative), intermediate (specimen-confined disease (pT2-3a, node negative PCa with negative surgical margins) but not in the favorable group), and unfavorable (the remaining patients)...
May 18, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28514930/hypofractionated-stereotactic-body-radiotherapy-for-localized-prostate-cancer-first-nordic-clinical-experience
#16
Kristiina Koskela, Jan-Erik Palmgren, Janne Heikkilä, Heli Virsunen, Liisa Sailas, Päivi Auvinen, Jan Seppälä, Vesa Kataja
BACKGROUND: The use of hypofractionated stereotactic body radiotherapy (SBRT) as primary treatment modality in clinically localized prostate cancer (PCa) is emerging, because the low α/β-ratio favors the use of high dose per fraction in PCa. There is a need for more data about SBRT, especially in high-risk PCa patients. The purpose of this retrospective study was to evaluate the safety and the short-term efficacy of robotic SBRT in a clinical patient cohort with localized PCa including also high-risk patients (D'Amico risk stratification)...
July 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28511371/study-of-serum-total-psa-and-free-psa-as-an-oncological-marker-in-breast-tumour
#17
Elteza Tahjiba Jahir, Runi Devi, Bibhuti Bhushan Borthakur
INTRODUCTION: Breast Cancer (BC) cases are rising alarmingly all over the world and India is not an exception. This rising trend is due to an increased age at first child birth, decreased breast feeding, and the changing lifestyle mostly in urban India. With the advent of more sensitive methodologies and research works in this field, it has been suggested that Prostate Specific Antigen (PSA) plays an important role in the pathogenesis of breast cancer besides other established tumour markers...
March 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28488030/-125-i%C3%A2-brachytherapy-in-younger-prostate-cancer-patients-outcomes-in-low-and-intermediate-risk-disease
#18
Isabelle Kindts, Karin Stellamans, Ignace Billiet, Hans Pottel, Antoon Lambrecht
PURPOSE: To evaluate local recurrence in younger men treated with low-dose-rate (LDR) (125)I brachytherapy (BT) for localized prostate cancer. PATIENTS AND METHODS: A total of 192 patients (≤65-years-old) were treated with LDR (125)I-BT ± hormone therapy. Local failure was defined as any prostate-specific antigen (PSA) rise leading to salvage treatment or biochemical failure according to the Phoenix definition. A bounce was defined as a rise in the nadir of ≥0...
May 9, 2017: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/28465697/the-effect-of-urethral-catheterization-on-the-level-of-prostate-specific-antigen
#19
Mohammad Hossein Izadpanahi, Hojatollah Salimi, Amir Javid, Salman Eslami
BACKGROUND: The normal prostate-specific antigen (PSA) level in patients with urethral catheterization is a controversy. We designed this study to investigate the effect of nontraumatic urethral catheterization without urinary retention on serum PSA. MATERIALS AND METHODS: Seventy patients scheduled for urethral catheterization before elective surgeries were randomly selected and included in the study. They were categorized into two age groups: 40-60 years (Group A) and over 60 years (Group B)...
2017: Journal of Research in Medical Sciences: the Official Journal of Isfahan University of Medical Sciences
https://www.readbyqxmd.com/read/28441008/simultaneous-detection-of-dual-prostate-specific-antigens-using-surface-enhanced-raman-scattering-based-immunoassay-for-accurate-diagnosis-of-prostate-cancer
#20
Ziyi Cheng, Namhyun Choi, Rui Wang, Sangyeop Lee, Kyung Chul Moon, Soo-Young Yoon, Lingxin Chen, Jaebum Choo
Accurate analysis of specific biomarkers in clinical serum is essential for early diagnosis and treatment of cancer. Here, a surface-enhanced Raman scattering (SERS)-based immunoassay, using magnetic beads and SERS nano tags, was developed for the determination of free to total (f/t) prostate specific antigen (PSA) ratio to improve the diagnostic performance of prostate cancer. To assess the clinical applicability of the proposed method, SERS-based assays for the simultaneous detection of dual PSA markers, free PSA (f-PSA) and complexed PSA (c-PSA), were performed for clinical samples in the gray zone between 4...
April 27, 2017: ACS Nano
keyword
keyword
68976
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"